ALBO News and Press, Albireo Pharma Inc.

Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...

Summary The backbone of the Albireo is Bylvay, a product in a platform already approved in one indication and expected to be approved in two significant larger indications. Ipsen recognizes the huge potential and is offering $42 plus a $10 CVR to acquire Albireo. The deal is expected to...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...

Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma ( NASDAQ: ALBO ) in reaction to its deal to be acquired by France's Ipsen. Ipsen on Monday said it would buy ALBO through a tender offer of $42/share for an estimated consideration of ~$952M ...

Summary Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia. Other younger pipeline assets for orphan diseases w...

The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are acquisition deals, clinica...

Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) is acquiring Albireo ( NASDAQ: ALBO ) in deal worth about $952M plus one contingent value right (CVR) per share to bolster its rare disease portfolio with treatments for pediatric liver diseases. Albireo's lead drug is Bylvay (odevixib...

Summary ALBO has one approved indication and one more filed for a label expansion. The company has begun a slow revenue stream and has decent cash. A small opportunity presents itself in the company's measured but steady growth. For further details see: Alb...